Structure Model Analysis Of Phosphorylation Dependent Binding And Sequestration Of SARS-COV-2 Encoded Nucleocapsid Protein By Protein 14-3-3
preprint
OA: closed
Abstract
Phosphorylation of serines 197 and 206 of SARS-COV-2 Nucleocapsid protein (NCp) enhanced the stability and binding efficiency and sequestration of NCp to Protein 14-3-3 by increasing the Stability Energy (ΔGstability energy) and Binding Energy (ΔΔGbinding energy) from ~545 Kcal/mol to ~616 Kcal/mol, and from 108 Kcal/mol to ~228 Kcal/mol respectively. The calculated Binding Energy Difference (ΔΔGbinding energy difference) between dephospho-NCp-14-3-3 complex and phospho-NCp-13-3-3 complex was ~72 Kcal/mol. Phosphorylations of serines 186, 197, 202 and 206, and threonines 198 and 205 NCp also caused an increase in the Stability Energy (ΔGstability energy) and Binding Energy (ΔΔGbinding energy) from ~545 Kcal/mol to ~617, 616, 583, 580, 574, 564 and 566 Kcal/mol and from ~108 Kcal/mol to ~228, 216, 184, 188, 184, 174 and 112 Kcal/mol respectively. Phosphorylation of NCp on serines 197 and 206 caused a decrease in Stability Energy and Binding Energy from ~698 Kcal/mol to 688 Kcal/mol, and from ~91 Kcal/mol to ~82 Kcal/mol for the dimerization of NCp. These results support the existence of a phosphorylation dependent cellular mechanism to bind and sequester NCp.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (2)
References (46)
- Phosphorylation modulates liquid-liquid phase separation of the SARS-CoV-2 N protein via crossref
- SARS-CoV-2 Nucleocapsid Assembly Inhibitors: Repurposing Antiviral and Antimicrobial Drugs Targeting Nucleocapsid-RNA Interaction via crossref
- doi:10.1038/s41586-020-2008-3 via crossref
- doi:10.1038/nature02145 via crossref
- doi:10.1126/science.1116480 via crossref
- doi:10.1038/nm1267 via crossref
- doi:10.1038/s41586-020-2179-y via crossref
- doi:10.1016/j.virol.2006.11.027 via crossref
- doi:10.1128/jvi.00569-10 via crossref
- doi:10.1128/jvi.01925-19 via crossref
- doi:10.1139/w08-139 via crossref
- doi:10.1016/j.jmb.2007.02.069 via crossref
- doi:10.1128/jvi.79.22.13848-13855.2005 via crossref
- doi:10.1074/jbc.m501015200 via crossref
- doi:10.1016/j.bbrc.2004.02.074 via crossref
- doi:10.1111/j.1742-4658.2008.06564.x via crossref
- doi:10.1016/j.bpc.2004.06.008 via crossref
- doi:10.1016/j.febslet.2005.09.038 via crossref
- doi:10.1016/s0140-6736(03)14962-8 via crossref
- doi:10.1016/j.apsb.2020.04.009 via crossref
- doi:10.1080/07391102.2020.1778536 via crossref
- doi:10.1016/j.vaccine.2006.01.058 via crossref
- doi:10.1038/sj.cr.7290158 via crossref
- doi:10.1016/j.virol.2006.03.036 via crossref
- doi:10.1016/j.micpath.2020.104236 via crossref
- doi:10.1128/jvi.00647-20 via crossref
- doi:10.1016/j.bbrc.2020.08.024 via crossref
- doi:10.1128/jvi.79.17.11476-11486.2005 via crossref
- doi:10.1074/jbc.m805747200 via crossref
- doi:10.1016/j.chom.2014.09.009 via crossref
- doi:10.1002/prot.24065 via crossref
- doi:10.1002/prot.24179 via crossref
- doi:10.1016/s0022-2836(02)00442-4 via crossref
- doi:10.1093/nar/gki387 via crossref
- doi:10.1093/bioinformatics/btu097 via crossref
- doi:10.1038/sj.cr.7290290 via crossref
- doi:10.1504/ijcbdd.2010.038396 via crossref
- doi:10.1371/journal.pone.0066273 via crossref
- doi:10.1016/j.str.2011.09.021 via crossref
- doi:10.1016/s0021-9258(18)43836-7 via crossref
- doi:10.1093/emboj/cdg426 via crossref
- doi:10.1016/s0092-8674(00)81067-3 via crossref
- doi:10.1016/s0092-8674(00)80487-0 via crossref
- doi:10.1016/s0140-6736(20)302518 via crossref
- doi:10.1016/j.molcel.2020.08.006 via crossref
- doi:10.1038/s41586-020-2012-7 via crossref
Source provenance
- crossref
- last seen: 2026-07-08T06:45:40.863650+00:00
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00
- unpaywall
- last seen: 2026-07-11T06:40:09.570059+00:00